Drug Profile
Research programme: WEE1 protein inhibitors - Almac Discovery
Alternative Names: Wee-1 inhibitor - Almac DiscoveryLatest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Almac Discovery
- Class Antineoplastics
- Mechanism of Action WEE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
- 30 May 2019 Debiopharm plans a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (PO) in June 2019 (NCT03968653)
- 20 Jun 2017 WEE-1 kinase inhibitor programme licensed to Debiopharm worldwide